Diagnosis and Management of Sarcoidosis-like Reaction in Adjuvant Immunotherapy: A Comprehensive Review and Clinical Implications
Open Access
- 10 May 2026
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 14 (5) , 1082
Abstract
Immune checkpoint inhibitors (ICIs) have transformed oncologic care and are increasingly used as adjuvant therapy to reduce the risk of recurrence. However, this shift has introduced immune-related adverse events (irAEs) to patients who may otherwise be clinically disease-free after definitive therapy. Sarcoidosis-like reaction (SLR) is an uncommon but important irAE characterized by non-necrotizing granulomatous inflammation. In the adjuvant setting, SLR is uniquely consequential because it can closely mimic recurrent malignancy on surveillance imaging and thereby prompt unnecessary diagnostic procedures, treatment interruption, or escalation of care. This review summarizes the current evidence on ICI-associated SLR with an emphasis on adjuvant immunotherapy, where practical guidance remains limited. We integrate evidence from clinical trials, real-world cohorts, and published case series to summarize the reported incidence of SLR, proposed immunologic mechanisms, clinical and radiographic presentation, pathology, differential diagnosis, and management. Particular attention is given to the problem of distinguishing SLR from recurrence, when tissue confirmation should be prioritized, and how management should be individualized according to clinical severity and organ involvement. Common radiographic features include bilateral mediastinal and hilar lymphadenopathy and pulmonary nodules, but tissue confirmation remains the diagnostic gold standard when feasible. Many cases are low grade and may be managed conservatively. Greater recognition of ICI-associated SLR is critical to avoid misdiagnosis and unnecessary escalation of care while preserving the therapeutic benefit of adjuvant immunotherapy.Keywords
This publication has 72 references indexed in Scilit:
- Can computed tomography findings and radiomics analysis of mediastinal lymph nodes differentiate between sarcoidosis and lymphoma?Clinical Radiology, 2024
- Survival Among Veterans Receiving Steroids for Immune-Related Adverse Events After Immune Checkpoint Inhibitor TherapyJAMA Network Open, 2023
- Frailty and checkpoint inhibitor toxicity in older patients with melanomaCancer, 2022
- Diagnosis and Treatment of Pulmonary SarcoidosisJAMA, 2022
- Sarcoidosis related to checkpoint and BRAF/MEK inhibitors in melanomaAutoimmunity Reviews, 2020
- Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasisEuropean Journal of Cancer, 2020
- Immune checkpoint inhibitor-induced sarcoidosis-like granulomasInternational Journal of Clinical Oncology, 2019
- Drug-Induced Sarcoidosis-Like ReactionsChest, 2018
- Diagnostic Utility of Angiotensin-Converting Enzyme in Sarcoidosis: A Population-Based StudyLung, 2015
- An immune-active tumor microenvironment favors clinical response to ipilimumabCancer Immunology, Immunotherapy, 2011